当前位置: 首页 >> 检索结果
141. Development and validation of the nomogram based on INR and eGFR for estimation of mortality in patients with acute-on-chronic hepatitis B liver failure.
作者: Shengnan Li.;Xiehua Zhang.;Qian Li.;Binyue Lv.;Yefan Zhang.;Jianwei Jia.;Xiaofen Yue.;Wei Lu.
来源: BMC Gastroenterol. 2021年21卷1期474页
Acute-on-chronic hepatitis B liver failure (ACHBLF) is a critical clinical syndrome with a high short-term mortality evolved from chronic hepatitis B (CHB)-related liver disease. Prediction of mortality risk and early intervention can improve the prognosis of patients. This study aimed to develop and validate the nomogram for short-time mortality estimation in ACHBLF patients defined according to Asian Pacific Association for the Study of the Liver (APASL).
142. Outcomes of endoscopic submucosal dissection for gastroesophageal reflux disease (ESD-G) for medication-refractory gastroesophageal reflux disease: 35 cases underwent ESD-G including 15 cases followed more than 5 years.
作者: Kazuhiro Ota.;Toshihisa Takeuchi.;Yuichi Kojima.;Noriaki Sugawara.;Shinya Nishida.;Taro Iwatsubo.;Shimpei Kawaguchi.;Satoshi Harada.;Satoshi Tokioka.;Kazuhide Higuchi.
来源: BMC Gastroenterol. 2021年21卷1期432页
Although some kinds of endoluminal surgery for patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD) have been reported, there are few reports on their long-term outcomes. In 2014, we reported the effectiveness of endoscopic surgery for PPI-refractory GERD, which we invented and named endoscopic submucosal dissection for GERD (ESD-G) in 2008. Thereafter, we accumulated more cases and monitored the patients' condition postoperatively and describe the outcomes herein.
143. Randomized Controlled-Feeding Study of Dietary Emulsifier Carboxymethylcellulose Reveals Detrimental Impacts on the Gut Microbiota and Metabolome.
作者: Benoit Chassaing.;Charlene Compher.;Brittaney Bonhomme.;Qing Liu.;Yuan Tian.;William Walters.;Lisa Nessel.;Clara Delaroque.;Fuhua Hao.;Victoria Gershuni.;Lillian Chau.;Josephine Ni.;Meenakshi Bewtra.;Lindsey Albenberg.;Alexis Bretin.;Liam McKeever.;Ruth E Ley.;Andrew D Patterson.;Gary D Wu.;Andrew T Gewirtz.;James D Lewis.
来源: Gastroenterology. 2022年162卷3期743-756页
Epidemiologic and murine studies suggest that dietary emulsifiers promote development of diseases associated with microbiota dysbiosis. Although the detrimental impact of these compounds on the intestinal microbiota and intestinal health have been demonstrated in animal and in vitro models, impact of these food additives in healthy humans remains poorly characterized.
144. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
作者: Bruce E Sands.;Laurent Peyrin-Biroulet.;Jaroslaw Kierkus.;Peter D R Higgins.;Monika Fischer.;Vipul Jairath.;Fumihito Hirai.;Geert D'Haens.;Ruth M Belin.;Debra Miller.;Elisa Gomez-Valderas.;April N Naegeli.;Jay L Tuttle.;Paul F Pollack.;William J Sandborn.
来源: Gastroenterology. 2022年162卷2期495-508页
Mirikizumab is a humanized monoclonal antibody targeting interleukin 23p19 with demonstrated efficacy in psoriasis and ulcerative colitis. We investigated the safety and efficacy of mirikizumab in patients with moderate-to-severe Crohn's disease (CD).
145. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.
作者: Rongrui Liu.;Lianke Liu.;Chuanhua Zhao.;Yuxian Bai.;Yulong Zheng.;Shu Zhang.;Ning Li.;Jianwei Yang.;Qingxia Fan.;Xiuwen Wang.;Shan Zeng.;Yingjun Zhang.;Weihong Zhang.;Yulei Zhuang.;Ning Kang.;Yingzhi Jiang.;Hongmei Sun.;Jianming Xu.
来源: BMC Gastroenterol. 2021年21卷1期398页
Larotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotinib in patients with advanced esophageal squamous cell carcinoma (ESCC) with EGFR overexpression or amplification pretreated with one or more system regimens, and to recommend an appropriate dose for its further study.
146. Comparison of sampling methods in assessing the microbiome from patients with ulcerative colitis.
作者: Dan Kim.;Jun-Young Jung.;Hyun-Seok Oh.;Sam-Ryong Jee.;Sung Jae Park.;Sang-Heon Lee.;Jun-Sik Yoon.;Seung Jung Yu.;In-Cheol Yoon.;Hong Sub Lee.
来源: BMC Gastroenterol. 2021年21卷1期396页
Dysbiosis of ulcerative colitis (UC) has been frequently investigated using readily accessible stool samples. However, stool samples might insufficiently represent the mucosa-associated microbiome status. We hypothesized that luminal contents including loosely adherent luminal bacteria after bowel preparation may be suitable for diagnosing the dysbiosis of UC.
147. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
作者: Jia-Yin Yao.;Min Zhang.;Wei Wang.;Xiang Peng.;Jun-Zhang Zhao.;Tao Liu.;Zhi-Wei Li.;Hai-Tian Sun.;Pinjin Hu.;Min Zhi.
来源: BMC Gastroenterol. 2021年21卷1期380页
Ustekinumab (UST), a newly-used biologic targeting p40 subunit of IL12 and IL23 in China, exerts a confirmed therapeutic effect on the induction and maintenance therapies for refractory Crohn's disease (CD). Therapeutic drug monitoring based on trough and antibody concentration is of core importance when treating patients who lose response to UST. We aimed to analyze the UST exposure-response relationship in CD treatment in the real-world setting.
148. PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis.
作者: William J Sandborn.;Larry C Mattheakis.;Nishit B Modi.;David Pugatch.;Brian Bressler.;Scott Lee.;Raj Bhandari.;Bittoo Kanwar.;Richard Shames.;Geert D'Haens.;Stefan Schreiber.;Silvio Danese.;Brian Feagan.;Rish K Pai.;David Y Liu.;Suneel Gupta.
来源: Gastroenterology. 2021年161卷6期1853-1864.e10页
Oral therapies targeting the integrin α4β7 may offer unique advantages for the treatment of inflammatory bowel disease. We characterized the oral α4β7 antagonist peptide PTG-100 in preclinical models and established safety, pharmacokinetic/pharmacodynamic relationships, and efficacy in a phase 2a trial in patients with ulcerative colitis (UC).
149. Sleeve Gastrectomy Confers Higher Risk of Gastroesophageal Reflux Disease Than Gastric Bypass: A Randomized Controlled Trial From the Oseberg Reflux Working Group.
作者: Jolanta Lorentzen.;Asle W Medhus.;Dag Hofsø.;Marius Svanevik.;Birgitte Seip.;Jøran Hjelmesæth.
来源: Gastroenterology. 2021年161卷6期2044-2046.e4页 150. Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma.
作者: Ken Kato.;Yoshinori Ito.;Isao Nozaki.;Hiroyuki Daiko.;Takashi Kojima.;Masahiko Yano.;Masaki Ueno.;Satoru Nakagawa.;Masakazu Takagi.;Shigeru Tsunoda.;Tetsuya Abe.;Tetsu Nakamura.;Morihito Okada.;Yasushi Toh.;Yuichi Shibuya.;Seiichiro Yamamoto.;Hiroshi Katayama.;Kenichi Nakamura.;Yuko Kitagawa.; .
来源: Gastroenterology. 2021年161卷6期1878-1886.e2页
Surgery is the standard of care for T1bN0M0 esophageal squamous cell carcinoma (ESCC), whereas chemoradiotherapy (CRT) is a treatment option. This trial aimed to investigate the noninferiority of CRT relative to surgery for T1bN0M0 ESCC.
151. Underwater vs Conventional Endoscopic Mucosal Resection of Large Sessile or Flat Colorectal Polyps: A Prospective Randomized Controlled Trial.
作者: Sandra Nagl.;Alanna Ebigbo.;Stefan Karl Goelder.;Christoph Roemmele.;Lukas Neuhaus.;Tobias Weber.;Georg Braun.;Andreas Probst.;Elisabeth Schnoy.;Agnieszka Jowita Kafel.;Anna Muzalyova.;Helmut Messmann.
来源: Gastroenterology. 2021年161卷5期1460-1474.e1页
Conventional endoscopic mucosal resection (CEMR) with submucosal injection is the current standard for the resection of large, nonmalignant colorectal polyps. We investigated whether underwater endoscopic mucosal resection (UEMR) is superior to CEMR for large (20-40mm) sessile or flat colorectal polyps.
152. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.
作者: Rohit Loomba.;Rizwana Mohseni.;K Jean Lucas.;Julio A Gutierrez.;Robert G Perry.;James F Trotter.;Robert S Rahimi.;Stephen A Harrison.;Veeral Ajmera.;Jeffrey D Wayne.;Marie O'Farrell.;William McCulloch.;Katharine Grimmer.;Mary Rinella.;Vincent Wai-Sun Wong.;Vlad Ratziu.;Gregory J Gores.;Brent A Neuschwander-Tetri.;George Kemble.
来源: Gastroenterology. 2021年161卷5期1475-1486页
Increased de novo lipogenesis creates excess intrahepatic fat and lipotoxins, propagating liver damage in nonalcoholic steatohepatitis. TVB-2640, a fatty acid synthase inhibitor, was designed to reduce excess liver fat and directly inhibit inflammatory and fibrogenic pathways. We assessed the safety and efficacy of TVB-2640 in patients with nonalcoholic steatohepatitis in the United States.
153. Influence of low FODMAP-gluten free diet on gut microbiota alterations and symptom severity in Iranian patients with irritable bowel syndrome.
作者: Kaveh Naseri.;Hossein Dabiri.;Mohammad Rostami-Nejad.;Abbas Yadegar.;Hamidreza Houri.;Meysam Olfatifar.;Amir Sadeghi.;Saeede Saadati.;Carolina Ciacci.;Paola Iovino.;Mohammad Reza Zali.
来源: BMC Gastroenterol. 2021年21卷1期292页
Recently, dietary restriction of fermentable carbohydrates (a low-FODMAP diet) in combination with a gluten-free diet (GFD) has been proposed to reduce the symptoms in irritable bowel syndrome (IBS) patients. Different studies reported that IBS has been associated with dysbiosis in the gut microbiota. Additionally, a few studies have reported inflammation in the gastrointestinal (GI) system of adults with IBS. In this study, we aimed to investigate the effects of low FODMAP-gluten free diet (LF-GFD) on clinical symptoms, intestinal microbiota diversity, and fecal calprotectin (FC) level in Iranian patients with IBS.
154. Return on investment of internet delivered exposure therapy for irritable bowel syndrome: a randomized controlled trial.
作者: Hugo Wallén.;Perjohan Lindfors.;Erik Andersson.;Erik Hedman-Lagerlöf.;Hugo Hesser.;Nils Lindefors.;Cecilia Svanborg.;Brjánn Ljótsson.
来源: BMC Gastroenterol. 2021年21卷1期289页
Irritable bowel syndrome (IBS) is a debilitating and costly disorder. Cognitive behavior therapy (CBT) is effective in the treatment of IBS, both when delivered over the internet and in face-to-face settings. CBT consists of different components and little is known about their relative importance. We have in an earlier study showed that inclusion of exposure in the CBT for IBS makes it even more effective. In the present study we wanted to evaluate the economic effects for society of inclusion vs exclusion of exposure in an internet delivered CBT for IBS.
155. Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study.
作者: Jessica W Crothers.;Nathaniel D Chu.;Le Thanh Tu Nguyen.;Magen Phillips.;Cheryl Collins.;Karen Fortner.;Roxana Del Rio-Guerra.;Brigitte Lavoie.;Peter Callas.;Mario Velez.;Aaron Cohn.;Ryan J Elliott.;Wing Fei Wong.;Elaine Vo.;Rebecca Wilcox.;Mark Smith.;Zain Kassam.;Ralph Budd.;Eric J Alm.;Gary M Mawe.;Peter L Moses.
来源: BMC Gastroenterol. 2021年21卷1期281页
Fecal microbiota transplantation (FMT) is a promising new strategy in the treatment of Inflammatory Bowel Disease, but long-term delivery systems are lacking. This randomized study was designed as a safety and feasibility study of long-term FMT in subjects with mild to moderate UC using frozen, encapsulated oral FMT (cFMT).
156. Cost effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome: the ACTIB randomised trial.
作者: Paul McCrone.;Hazel Everitt.;Sabine Landau.;Paul Little.;Felicity L Bishop.;Gilly O'Reilly.;Alice Sibelli.;Rachel Holland.;Stephanie Hughes.;Sula Windgassen.;Kim Goldsmith.;Nicholas Coleman.;Robert Logan.;Trudie Chalder.;Rona Moss-Morris.
来源: BMC Gastroenterol. 2021年21卷1期276页
Telephone therapist delivered CBT (TCBT) and web-based CBT (WCBT) have been shown to be significantly more clinically effective than treatment as usual (TAU) at reducing IBS symptom severity and impact at 12 months in adults with refractory IBS. In this paper we assess the cost-effectiveness of the interventions.
157. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
作者: Laurent Peyrin-Biroulet.;Edward V Loftus.;Jean-Frédéric Colombel.;Silvio Danese.;Raquel Rogers.;Jeffrey D Bornstein.;Jingjing Chen.;Stefan Schreiber.;Bruce E Sands.;Richard A Lirio.
来源: Gastroenterology. 2021年161卷4期1156-1167.e3页
VARSITY (An Efficacy and Safety Study of Vedolizumab Intravenous [IV] Compared to Adalimumab Subcutaneous [SC] in Participants With Ulcerative Colitis) showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab vs adalimumab. This analysis compared histologic outcomes.
158. Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial.
作者: Stefano Francesco Crinò.;Roberto Di Mitri.;Nam Q Nguyen.;Ilaria Tarantino.;Germana de Nucci.;Pierre H Deprez.;Silvia Carrara.;Masayuki Kitano.;Vanessa M Shami.;Gloria Fernández-Esparrach.;Jan-Werner Poley.;Francisco Baldaque-Silva.;Takao Itoi.;Erminia Manfrin.;Laura Bernardoni.;Armando Gabbrielli.;Elisabetta Conte.;Elettra Unti.;Jeevinesh Naidu.;Andrew Ruszkiewicz.;Michele Amata.;Rosa Liotta.;Gianpiero Manes.;Franca Di Nuovo.;Ivan Borbath.;Mina Komuta.;Laura Lamonaca.;Daoud Rahal.;Keiichi Hatamaru.;Masahiro Itonaga.;Gianenrico Rizzatti.;Guido Costamagna.;Frediano Inzani.;Mariangela Curatolo.;Daniel S Strand.;Andrew Y Wang.;Àngels Ginès.;Oriol Sendino.;Marianna Signoretti.;Lydi M J W van Driel.;Karoly Dolapcsiev.;Yukitoshi Matsunami.;Schalk van der Merwe.;Hannah van Malenstein.;Francesca Locatelli.;Loredana Correale.;Aldo Scarpa.;Alberto Larghi.
来源: Gastroenterology. 2021年161卷3期899-909.e5页
The benefit of rapid on-site evaluation (ROSE) on the diagnostic accuracy of endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) has never been evaluated in a randomized study. This trial aimed to test the hypothesis that in solid pancreatic lesions (SPLs), diagnostic accuracy of EUS-FNB without ROSE was not inferior to that of EUS-FNB with ROSE.
159. A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
作者: James D Lewis.;Robert S Sandler.;Carol Brotherton.;Colleen Brensinger.;Hongzhe Li.;Michael D Kappelman.;Scott G Daniel.;Kyle Bittinger.;Lindsey Albenberg.;John F Valentine.;John S Hanson.;David L Suskind.;Andrea Meyer.;Charlene W Compher.;Meenakshi Bewtra.;Akriti Saxena.;Angela Dobes.;Benjamin L Cohen.;Ann D Flynn.;Monika Fischer.;Sumona Saha.;Arun Swaminath.;Bruce Yacyshyn.;Ellen Scherl.;Sara Horst.;Jeffrey R Curtis.;Kimberly Braly.;Lisa Nessel.;Maureen McCauley.;Liam McKeever.;Hans Herfarth.; .
来源: Gastroenterology. 2021年161卷3期837-852.e9页
This study compared the effectiveness of the Specific Carbohydrate Diet (SCD) to the Mediterranean diet (MD) as treatment for Crohn's disease (CD) with mild to moderate symptoms.
160. Consumption of OLL1073R-1 yogurt improves psychological quality of life in women healthcare workers: secondary analysis of a randomized controlled trial.
作者: Tetsu Kinoshita.;Koutatsu Maruyama.;Keiko Suyama.;Mariko Nishijima.;Kimiko Akamatsu.;Akiko Jogamoto.;Kikumi Katakami.;Isao Saito.
来源: BMC Gastroenterol. 2021年21卷1期237页
We conducted a randomized controlled trial to investigate the effects of consumption of yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 in women healthcare workers. In a previous study we used these data to investigate hypothesized preventive effects against flu, however any effects on improving mental quality of life were not analyzed at that time. In the present study, we focus on that aspect.
|